SAO PAULO (Reuters) – Danish drugmaker Novo Nordisk will certainly spend 864 million reais ($ 158.2 million) to overhaul a plant in Brazil in charge of draining a quarter of its insulin manufacturing around the world, the company stated on Friday.
The funds will certainly upgrade the Montes Claros manufacturing facility, in the southeastern state of Minas Gerais, and apply lasting jobs there, Novo Nordisk stated in a declaration.
The manufacturer of Ozempic and Wegovy, which have actually blown up in appeal for their usage as weight-loss medicines, made the news public as Brazilian President Luiz Inacio Lula da Silva fulfilled previously in the day with Queen Mary Donaldson of Denmark, the Brazilian federal government stated in a declaration.
($ 1 = 5.4627 reais)
(Reporting by Andre Romani and Paula Arend Laier; Editing by Gabriel Araujo and Kylie Madry)
